Sebastian Sommer
Overview
Explore the profile of Sebastian Sommer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mogele T, Hock M, Sommer F, Friedrich L, Sommer S, Schmutz M, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766073
Background/objectives: Locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). As this approach achieves complete pathologic remissions (pCR) in approximately 30% of patients,...
2.
Dintner S, Schmutz M, Sommer S, Langer A, Hirschbuhl K, Claus R, et al.
Pathologie (Heidelb)
. 2023 Nov;
44(Suppl 3):155-159.
PMID: 37975919
The diagnosis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), originally based on morphological assessment alone, has to bring together more and more disciplines. Today, modern AML/MDS diagnostics rely...
3.
Sommer S, Schmutz M, Schaller T, Mayr P, Dintner S, Markl B, et al.
Cancer Rep (Hoboken)
. 2023 Nov;
7(1):e1916.
PMID: 37950626
Background: Inflammatory myofibroblastic tumor (IMTs) are rare mesenchymal neoplasms with slow growth. Resection is considered as therapeutic standard, with chemotherapy being insufficiently effective in advanced disease. ALK translocations are present...
4.
Luke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291825
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the...
5.
Jordan F, Huber S, Sommer S, Schenkirsch G, Fruhwald M, Trepel M, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34204522
The knowledge of inherited cancer susceptibility opens a new field of cancer medicine. We conducted a retrospective single-center cohort study. Data of AYA cancer patients registered between January 2014 and...
6.
Venhuizen J, Span P, van den Dries K, Sommer S, Friedl P, Zegers M
Cancers (Basel)
. 2019 Oct;
11(10).
PMID: 31569498
Tumor metastasis is the endpoint of tumor progression and depends on the ability of tumor cells to locally invade tissue, transit through the bloodstream and ultimately to colonize secondary organs...
7.
Venhuizen J, Sommer S, Span P, Friedl P, Zegers M
Sci Rep
. 2019 Jan;
9(1):90.
PMID: 30643202
P120 catenin (p120) is a non-redundant master regulatory protein of cadherin-based cell-cell junctions, intracellular signaling, and tissue homeostasis and repair. Alternative splicing can generate p120 isoforms 1 and 3 (p120-1...
8.
Sommer S, Cruijsen M, Claus R, Bertz H, Wasch R, Marks R, et al.
Leuk Res
. 2018 Aug;
72:20-26.
PMID: 30064039
The combination of 5-azacytidine (AZA) with donor lymphocyte infusions (DLIs) can induce remissions in patients with relapsed myeloid malignancies after allo-HCT. As decitabine (DAC) is known to be effective also...
9.
Flotho C, Sommer S, Lubbert M
Semin Cancer Biol
. 2017 Nov;
51:68-79.
PMID: 29129488
Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia....
10.
Ansari S, Paul E, Sommer S, Lieleg C, He Q, Daly A, et al.
J Biol Chem
. 2016 May;
291(19):9938.
PMID: 27197204
No abstract available.